2 citations
,
March 2020 in “Baghdad Science Journal” This study found that among men with Benign Prostatic Hyperplasia, treatment with the 5α-reductase inhibitor finasteride for three months significantly reduced levels of dihydrotestosterone and estradiol, hormones involved in prostate enlargement, without altering follicle-stimulating hormone or luteinizing hormone levels.
April 2013 in “e-Jurnal Medika Udayana” This abstract indicates that finasteride, at a dose of 1 mg per day, is effective in treating androgenetic alopecia in men by significantly reducing DHT levels.
2 citations
,
September 2009 in “Hormone Molecular Biology and Clinical Investigation” This study found that low-dose finasteride treatment in men with premature androgenetic alopecia decreased levels of 5α-reduced steroids, which may be linked to increased depression symptoms.
9 citations
,
January 2009 in “PubMed” This study found that finasteride treatment in men with benign prostate hyperplasia significantly altered steroid hormone profiles and may contribute to depressive symptoms by affecting neuroactive steroid levels.
4 citations
,
September 2006 in “European Urology Supplements” Dutasteride reduces DHT and improves BPH symptoms more effectively than finasteride.
This study suggests that the negative impact of high-dose Finasteride on male reproductive function may be mitigated by concurrent administration with TU.
408 citations
,
May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.
June 2001 in “International Journal of Cosmetic Surgery and Aesthetic Dermatology” This review discusses advances in 5α-reductase inhibitors for treating male androgenetic alopecia and reports no new clinical results.
3 citations
,
June 1996 in “PubMed” This review discusses the effects and potential benefits of finasteride in treating hirsutism and androgenetic alopecia but reports no new clinical results.
93 citations
,
January 1996 in “Clinical Pharmacokinectics” Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.
73 citations
,
January 1994 in “European Urology” This study found that finasteride significantly reduced serum dihydrotestosterone levels, confirming its efficacy as a 5a-reductase inhibitor, while Permixon showed no effect in healthy male volunteers.
12 citations
,
January 1993 in “PubMed” This review discusses the pharmacology and clinical use of finasteride for benign prostatic hyperplasia and reports its effectiveness in reducing prostate size and symptoms, though success varies among patients.
124 citations
,
January 1993 in “The Prostate” Finasteride effectively inhibits 5α reductase, while plant extracts like Permixon and Bazoton don't show significant results.